| [1] |
Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma[J]. Best Pract Res Clin Gastroenterol, 2015, 29(2):221-232.
|
| [2] |
Cardinale V, Semeraro R, Torrice A, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors[J]. World J Gastrointest Oncol, 2010, 2(11):407-416.
|
| [3] |
Alvaro D, Crocetti E, Ferretti S, et al. Descriptive epidemiology of cholangiocarcinoma in Italy[J]. Dig Liver Dis, 2010, 42(7):490-495.
|
| [4] |
Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma[J]. Gastroenterology, 2013, 145(6):1215-1229.
|
| [5] |
Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma[J]. Hepatology, 2011, 54(1):173-184.
|
| [6] |
Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis[J]. Cancer, 2000, 88(11):2471-2477.
|
| [7] |
Tanaka M, Tanaka H, Tsukuma H, et al. Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus[J]. J Viral Hepat, 2010, 17(10):742-748.
|
| [8] |
费健，韩天权．胆管癌流行病学、危险因素及分型、分期的研究进展[J/CD]．中华肝脏外科手术学电子杂志，2015，4(4):199-201.
|
| [9] |
Lamarca A, Hubner RA, David Ryder W, et al. Second-line chemotherapy in advanced biliary cancer: a systematic review[J]. Ann Oncol, 2014, 25(12):2328-2338.
|
| [10] |
Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes[J]. Hepatology, 2012, 55(6):1876-1888.
|
| [11] |
Kumagai S, Kurumatani N, Arimoto A, et al. Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane[J]. Occup Environ Med, 2013, 70(7):508-510.
|
| [12] |
Weber SM, Ribero D, O'Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement[J]. HPB, 2015, 17(8):669-680.
|
| [13] |
Ribero D, Pinna AD, Guglielmi A, et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients[J]. Arch Surg, 2012, 147(12):1107-1113.
|
| [14] |
Farges O, Fuks D, Boleslawski E, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group[J]. Ann Surg, 2011, 254(5):824-829.
|
| [15] |
Uenishi T, Ariizumi S, Aoki T, et al. Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery[J]. J Hepatobiliary Pancreat Sci, 2014, 21(7):499-508.
|
| [16] |
de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment[J]. J Clin Oncol, 2011, 29(23):3140-3145.
|
| [17] |
Ito T, Ebata T, Yokoyama Y, et al. The pathologic correlation between liver and portal vein invasion in perihilar cholangiocarcinoma: evaluating the oncologic rationale for the American Joint Committee on Cancer definitions of T2 and T3 tumors[J]. World J Surg, 2014, 38(12):3215-3221.
|
| [18] |
Ebata T, Yokoyama Y, Igami T, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients[J]. Ann Surg, 2012, 256(2):297-305.
|
| [19] |
Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases[J]. Ann Surg, 2010, 252(1):115-123.
|
| [20] |
Ebata T, Kosuge T, Hirano S, et al. Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas[J]. Br J Surg, 2014, 101(2):79-88.
|
| [21] |
Eckel F, Schmid RM. Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials[J]. Chemotherapy, 2014, 60(1):13-23.
|
| [22] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281.
|
| [23] |
Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan[J]. Br J Cancer, 2010, 103(4):469-474.
|
| [24] |
Lamarca A, Benafif S, Ross P, et al. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: effective intervention in patients with luminal disease[J]. Eur J Cancer, 2015, 51(13):1694-1703.
|